AlphaStocks
3.5
Weak

ADMA BIOLOGICS, INC. (ADMA)

Health Care / Biotechnology

S&P SmallCap 600

$9.11

Scores poorly across most models. Proceed with caution.

Weak

Score based on 4 of 5 models — moderate confidence

#942out of 1127 in Health Care

Is ADMA BIOLOGICS, INC. a Good Investment in 2026?

ADMA BIOLOGICS, INC. (ADMA) scores 3.5 out of 10 on AlphaStocks' composite model, earning a Weak rating. The Lynch model rates ADMA BIOLOGICS, INC. as Strong. However, the Graham model rates it Caution — 50% above fair value. ADMA BIOLOGICS, INC. currently trades below its estimated fair value of $14, suggesting potential upside. ADMA BIOLOGICS, INC. ranks #942 out of 1127 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E15.2ROE22.0Market Cap2B

Estimated Fair Value

$14.4537% below

Fair value above market price. ROE of 22% signals strong profitability. P/E of 15x is moderate for this quality level.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Attractive

5/9

Buffett

Attractive

Business quality & competitive moat

Graham

Caution

50% above fair value

Lynch

Strong

Growth rate vs price (PEG)

Greenblatt

Strong

Top 25% (rank 24%)

Frequently Asked Questions

Is ADMA BIOLOGICS, INC. (ADMA) a good investment?
Based on AlphaStocks' composite analysis, ADMA BIOLOGICS, INC. (ADMA) scores 3.5 out of 10, earning a Weak rating. This score is below average, suggesting caution. Fair value above market price. ROE of 22% signals strong profitability. P/E of 15x is moderate for this quality level.
What is ADMA BIOLOGICS, INC.'s Piotroski F-Score?
ADMA BIOLOGICS, INC.'s Piotroski F-Score status is Attractive. The raw score is 5/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is ADMA overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $14, ADMA appears undervalued. The stock currently trades 37% below its estimated fair value. Fair value above market price. ROE of 22% signals strong profitability. P/E of 15x is moderate for this quality level.
How does ADMA compare to other Health Care stocks?
ADMA BIOLOGICS, INC. ranks #942 out of 1127 stocks in the Health Care sector, placing it in the top 84% of its sector by composite score. There are higher-ranked alternatives in this sector worth exploring.
What do investment models say about ADMA?
AlphaStocks evaluates ADMA using five proven investment models. Piotroski: Attractive; Buffett: Attractive; Graham: Caution; Lynch: Strong; Greenblatt Magic Formula: Strong. These models are combined into a single composite score of 3.5/10.

Similar Stocks

PARRFTIAZN

Compare ADMA with

ADMA vs PARRADMA vs FTIADMA vs AZN

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer